ChemomAb 
Welcome,         Profile    Billing    Logout  
 0 Products   0 Diseases   0 Products   0 Trials   0 News 


12»
  • ||||||||||  bortezomib / Generic mfg., sepantronium bromide (PC-002) / Cothera Biosci, ADT-007 / ADT Pharma, ChemomAb
    Preclinical, Journal:  Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models. (Pubmed Central) -  Mar 10, 2025   
    ADT-007 exhibited high potency and selectivity in KRAS-mutant BOTs, reducing tumor burdens >30% at nanomolar concentrations, and demonstrated superior selectivity over bortezomib and YM155 with minimal cytotoxicity in RAS-WT BOTs...This study also underscores the translational utility of 3D BOT models for preclinical drug response assessment. Further validation in patient-derived BOTs is necessary to evaluate potential of ADT-007 in clinical settings.
  • ||||||||||  ADT-007 / ADT Pharma, ChemomAb
    Preclinical Development of a Novel Pan-RAS Inhibitor Against Relapsed/Refractory Multiple Myeloma (Halls G-H (San Diego Convention Center)) -  Nov 6, 2024 - Abstract #ASH2024ASH_5367;    
    Next, we plan to evaluate the antitumor activity of ADT-1004 in mouse xenograft models of human myeloma using immunocompromised mice. Our research will lay the groundwork for future development efforts needed to advance ADT-1004 to clinical trials involving patients with RRMM.
  • ||||||||||  CM-101 subcutaneous / ChemomAb, CM-101 intravenous / ChemomAb
    P1 data, Journal:  Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. (Pubmed Central) -  Jun 1, 2024   
    P1, P1b
    These findings support clinical trials of ADT-1004 for KRAS mutant PDAC. In healthy volunteers and patients with MASLD without evidence of MASH, IV and SC CM-101 was well tolerated at doses ranging from 0.75 mg/kg to10.0 mg/kg and engaged its target (i.e., CCL24), indicating therapeutic potential in treating inflammatory and fibrotic diseases.
  • ||||||||||  CM-101 subcutaneous / ChemomAb
     (Track Hub: Basic Science) -  Apr 29, 2024 - Abstract #EASLILC2024EASL_ILC_2605;    
    P2a
    Additionally, a protein signature generated from CCL24-activated HSC predicted PSC disease and its severity, underscoring the relevance of this translational assay to PSC. These findings support CM-101's mode of action in liver fibrosis and may serve as a translational tool in the ongoing clinical trial in PSC.
  • ||||||||||  ADT-007 / ADT Pharma, ChemomAb, ADT-1004 / Auburn University, ADT Pharma
    A potent and selective pan-RAS inhibitor, ADT-1004, targeting complex KRAS mutations for pancreatic cancer. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_4742;    
    ADT-1004 inhibited tumor growth of KRAS mutant PDA tumors by targeting activated RAS to disrupt downstream MAPK/AKT signaling. The results highlight the promise of ADT-1004 as a novel pan-RAS inhibitor and open new strategies for addressing the complex genetic landscape of PDAC and other RAS driven cancers.
  • ||||||||||  CM-101 subcutaneous / ChemomAb
     (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_937;    
    P2a
    Additionally, a protein signature generated from CCL24-activated HSC predicted PSC disease and its severity, underscoring the relevance of this translational assay to PSC. These findings support CM-101's mode of action in liver fibrosis and may serve as a translational tool in the ongoing clinical trial in PSC.
  • ||||||||||  nebokitug intravenous (CM-101 intravenous) / ChemomAb
    Enrollment closed, Phase classification:  CM-101 in PSC Patients -The SPRING Study (clinicaltrials.gov) -  Jan 9, 2024   
    P2,  N=68, Active, not recruiting, 
    Daily oral administration of ADT-1004 significantly inhibited RAS signaling and tumor growth in orthotopic and PDX mouse models of pancreatic cancer. Recruiting --> Active, not recruiting | Phase classification: P2a --> P2
  • ||||||||||  CM-101 intravenous / ChemomAb
    A PROOF OF BIOLOGICAL CONCEPT TRIAL OF CM101 TO TARGET CCL24 IN SYSTEMIC SCLEROSIS: A BIOMARKER INFORMED, PRECISION MEDICINE APPROACH () -  May 19, 2023 - Abstract #EULAR2023EULAR_2966;    
    Conclusion This novel, biomarker enriched clinical trial, will determine the biological activity of CM101 in patients with active vascular or fibrotic SSc, across limited and cutaneous subsets, and inform future development of CM101 in SSc. Bridging biomarker science with clinical trial design carries the opportunity of improving the efficiency in subsequent clinical development and allows for a targetted treatment approach.
  • ||||||||||  nebokitug intravenous (CM-101 intravenous) / ChemomAb
    Enrollment change, Trial completion date, Trial primary completion date:  CM-101 in PSC Patients -The SPRING Study (clinicaltrials.gov) -  Mar 22, 2023   
    P2a,  N=93, Recruiting, 
    Bridging biomarker science with clinical trial design carries the opportunity of improving the efficiency in subsequent clinical development and allows for a targetted treatment approach. N=45 --> 93 | Trial completion date: Sep 2022 --> Sep 2025 | Trial primary completion date: Jun 2022 --> Sep 2024
  • ||||||||||  ADT-007 / ADT Pharma, ChemomAb, ADT-1004 / Auburn University
    Antitumor activity of 1st-in-class pan-RAS inhibitor ADT-1004 in mouse models of pancreatic ductal adenocarcinoma (Section 35; Poster Board #13) -  Mar 14, 2023 - Abstract #AACR2023AACR_8010;    
    ADT-1004 represents a 1st-in-class pan-RAS inhibitor with potential advantages over mutant-specific KRAS inhibitors for greater efficacy and ability to avert mechanisms of resistance. These data support future clinical trials of ADT-1004 as a monotherapy for the treatment of patients with PDA regardless of the underlying mutation.
  • ||||||||||  ADT-007 / ADT Pharma, ChemomAb
    Oncogenic KRAS inhibition with ADT-007 primes T cell responses in pancreatic ductal adenocarcinoma (Section 25; Poster Board #2) -  Mar 14, 2023 - Abstract #AACR2023AACR_6294;    
    The small molecule inhibitor, ADT-007 blocks oncogenic KRAS signaling and modulates T cell activation and function in the TiME of immune competent, syngeneic mouse models of PDAC. More broadly, these findings indicate that a pan-RAS inhibitor is capable of modulating anti-tumor immune responses extending previous observations that targeted inhibition of oncogenic KRASG12C modulates tumor immunity in animal models of colon and lung cancer.
  • ||||||||||  ADT-007 / ADT Pharma, ChemomAb
    ADT-007 binds RAS and inhibits RAS signaling (Section 18; Poster Board #15) -  Mar 14, 2023 - Abstract #AACR2023AACR_3901;    
    Finally, ADT-007 demonstrated RAS-selective growth inhibition in isogenic pancreatic and colorectal cancer cell pairs (BxPC-3, HT29). Together, these experiments support further development of ADT-007 and related analogs for treatment of RAS-driven cancers.
  • ||||||||||  ADT-007 / ADT Pharma, ChemomAb
    Validation of a novel pan-Ras inhibitor, ADT-007, against lethal variants of prostate cancer (Section 17; Poster Board #28) -  Mar 14, 2023 - Abstract #AACR2023AACR_3883;    
    Finally, using PCa patient datasets, we showed that ADT-007 is potentially capable of reversing the expression of several genes associated with biochemical recurrence. Thus, our results show that ADT-007 is a novel drug candidate that circumvents subclonal aggressiveness, drug resistance, and stemness in lethal PCa through simultaneous inhibition of multiple oncogenic factors/pathways.
  • ||||||||||  PF-02545920 / Pfizer, MCI-030 / ChemomAb
    Journal:  Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer. (Pubmed Central) -  Nov 4, 2022   
    Using small molecule inhibitors, Pf-2545920 and a novel NSAID-derived PDE10A inhibitor, MCI-030, we show that PDE10A inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis...We also demonstrate that PDE10A inhibition leads to decreased Wnt-induced β-catenin nuclear translocation, as well as decreased EGF-mediated activation of RAS/MAPK and AKT pathways in ovarian cancer cells. These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment.
  • ||||||||||  nebokitug intravenous (CM-101 intravenous) / ChemomAb
    Trial completion date, Trial primary completion date:  CM-101 in PSC Patients -The SPRING Study (clinicaltrials.gov) -  Sep 2, 2021   
    P2a,  N=45, Recruiting, 
    These findings implicate PDE10A as novel target for ovarian cancer chemoprevention and treatment. Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Jun 2022
  • ||||||||||  nebokitug intravenous (CM-101 intravenous) / ChemomAb
    Trial completion date, Trial primary completion date:  CM-101 in PSC Patients -The SPRING Study (clinicaltrials.gov) -  Aug 25, 2021   
    P2a,  N=45, Recruiting, 
    Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Mar 2022 --> Jun 2022 Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Sep 2021 --> Mar 2022
  • ||||||||||  nebokitug intravenous (CM-101 intravenous) / ChemomAb
    New P2a trial:  CM-101 in PSC Patients -The SPRING Study (clinicaltrials.gov) -  Oct 22, 2020   
    P2a,  N=45, Recruiting, 
  • ||||||||||  inodiftagene vixteplasmid (BC 819) / Anchiano Therap
    Review, Journal:  Long non-coding RNA in bladder cancer. (Pubmed Central) -  Sep 25, 2020   
    Moreover, antisense oligonucleotides (ASOs) and a double-stranded DNA plasmid (BC-819) have been designed for use in preclinical cancer models and clinical trials in patients. Therefore, the results of investigations have gradually prompted the utility of lncRNAs.
  • ||||||||||  inodiftagene vixteplasmid (BC 819) / ChemomAb
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC (clinicaltrials.gov) -  Aug 19, 2020   
    P2,  N=32, Terminated, 
    Therefore, the results of investigations have gradually prompted the utility of lncRNAs. N=140 --> 32 | Trial completion date: Nov 2021 --> Dec 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Nov 2019; Lack of efficacy
  • ||||||||||  CM-101 / ChemomAb
    Journal:  A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. (Pubmed Central) -  Feb 13, 2020   
    Antifibrotic and anti-inflammatory effects of CM-101 were tested in the MCD and STAM mouse models and in the thioacetamide (TAA) model in rats...It was found to be significantly expressed in patients with non-alcoholic steatohepatitis, in whom it regulates profibrotic processes in the liver. Herein, we show that blockade of CCL24 using a monoclonal antibody robustly attenuated liver fibrosis and inflammation in animal models, thus suggesting a potential therapeutic role for an anti-CCL24 agent.
  • ||||||||||  inodiftagene vixteplasmid (BC 819) / ChemomAb
    Enrollment closed:  Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC (clinicaltrials.gov) -  Nov 18, 2019   
    P2,  N=140, Active, not recruiting, 
    The mechanism of solvent-evolution-induced decomposition in ICM-101 solvates was further studied, and it was found that solvent evolution might produce defects in the crystals of ICM-101 solvates, and induce the decomposition of ICM-101 on the defects. Recruiting --> Active, not recruiting
  • ||||||||||  CM-101 / ChemomAb
    CM-101 A NOVEL CCL24 BLOCKING MONOCLONAL ANTIBODY ATTENUATES HSC ACTIVATION IN VITRO AND REDUCES FIBROSIS IN THE TAA MICE MODEL (Hynes Convention Center, Hall B) -  Sep 29, 2019 - Abstract #AASLD2019AASLD_2679;    
    Treatment of HSC with CCL24 induced their activation affecting motility and expression of fibrotic markers, α-SMA and pro Collagen I. CCL24 blockade using CM-101 a specific anti-CCL24 monoclonal antibody reversed these effects both in-vitro and in-vivo. These findings further support the role of CCL24 in development of liver fibrosis and suggest that CCL24 blockade has a potential therapeutic role in liver fibrosis related diseases.
  • ||||||||||  inodiftagene vixteplasmid (BC 819) / ChemomAb
    Trial completion, Phase classification:  Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer (clinicaltrials.gov) -  Apr 30, 2019   
    P2b,  N=47, Completed, 
    These findings further support the role of CCL24 in development of liver fibrosis and suggest that CCL24 blockade has a potential therapeutic role in liver fibrosis related diseases. Active, not recruiting --> Completed | Phase classification: P2 --> P2b
  • ||||||||||  inodiftagene vixteplasmid (BC 819) / ChemomAb
    Enrollment open, Trial initiation date:  Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC (clinicaltrials.gov) -  Dec 19, 2018   
    P2,  N=140, Recruiting, 
    Recruiting --> Completed | N=18 --> 38 | Trial completion date: Sep 2014 --> Oct 2017 Not yet recruiting --> Recruiting | Initiation date: Nov 2019 --> Dec 2018